학술논문
Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod.
Document Type
Article
Author
Source
Subject
*COVID-19 vaccines
*MULTIPLE sclerosis
*ANTIBODY formation
*COVID-19
*NEUROMYELITIS optica
*
*
*
*
Language
ISSN
1110-1083
Abstract
COVID-19, Multiple sclerosis, Anti-COVID-19 vaccination, Sphingosine 1-phosphate receptor, Modulators, Disease-modifying therapy Keywords: COVID-19; Multiple sclerosis; Anti-COVID-19 vaccination; Sphingosine 1-phosphate receptor; Modulators; Disease-modifying therapy EN COVID-19 Multiple sclerosis Anti-COVID-19 vaccination Sphingosine 1-phosphate receptor Modulators Disease-modifying therapy 1 2 2 12/20/21 20211214 NES 211214 To the editor, We appreciated Mansoor and colleagues review entitled "COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease-modifying therapies: "what the bleep do we know?" [[1]]. [Extracted from the article]